Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients.
Aleksander KragMarcus SchuchmannHanna SodatonouJeff PilotJames WhitehouseSimone I StrasserMark HudsonPublished in: Hepatology, medicine and policy (2018)
ClinicalTrials.gov identifier NCT02488993.